Masato Iwasaki, president of the Japan Pharma Business Unit at Takeda Pharmaceutical, will step down from the position, it has been learned. He will remain as a member of the board and executive team at the company, while taking up…
To read the full story
Related Article
- Takeda’s Iwasaki to Retire as Representative Director
March 31, 2023
- Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
- Takeda Appoints Milano Furuta as New Japan Chief
March 16, 2021
BUSINESS
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Daiichi Starts Global PIII of Datroway in Adjuvant Urothelial Cancer
August 28, 2026
- FDA Accepts Kowa’s Glaucoma Drug K-911 for Review
August 28, 2026
- Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage
August 28, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





